Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc (NQ: OVID )

1.140 UNCHANGED
Streaming Delayed Price Updated: 3:02 PM EDT, Aug 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 102,432
Open 1.130
Bid (Size) 1.120 (6)
Ask (Size) 1.140 (61)
Prev. Close 1.140
Today's Range 1.090 - 1.140
52wk Range 0.6800 - 4.139
Shares Outstanding 70,417,345
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts
Via Benzinga
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024
OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-65.66%
-65.66%
1 Month
+10.68%
+10.68%
3 Month
-63.69%
-63.69%
6 Month
-69.35%
-69.35%
1 Year
-71.03%
-71.03%

More News

Read More
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
The Latest Analyst Ratings For Ovid Therapeutics
Via Benzinga
Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Ovid Therapeutics to Present at Upcoming August Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
From Ovid Therapeutics Inc.
Via GlobeNewswire
7 Sorry Biotech Stocks Set to Make Investors Sad
Via InvestorPlace
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
From Ovid Therapeutics Inc.
Via GlobeNewswire
Nasdaq Surges Over 200 Points; Aaron's Shares Jump
Via Benzinga
Is the Stock Market Closed on Juneteenth 2024?
Via InvestorPlace
ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation
Via InvestorPlace
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal
Via InvestorPlace
Why Is Ovid Therapeutics (OVID) Stock Down 69% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
US Stocks Mixed; Dow Tumbles Over 100 Points
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
Via Benzinga
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
From Ovid Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.